Introduction {#s1}
============

Systemic inflammation induces brain neuronal inflammation \[[@r23]\]. Neuronal inflammation can cause postoperative cognitive disorder (POCD) and delirium \[[@r30]\], which have significant morbidity and mortality \[[@r23]\]. There is no cure for neuronal inflammation, so clinicians focus on treating the systemic inflammation.

Sevoflurane is a widely used inhalational anesthetic in clinical practice. Preclinical data suggest that sevoflurane preconditioning can induce ischemic tolerance neuroprotection \[[@r18], [@r36], [@r38]\]. The mechanisms of sevoflurane preconditioning might be associated with the inhibition of microglial activation \[[@r24]\], which is a crucial factor in brain inflammation \[[@r5]\]. Sevoflurane prevents lipopolysaccharide (LPS)-induced barrier dysfunction in human lung microvascular endothelial cells \[[@r12]\] and LPS-induced myocardial inflammation \[[@r19]\]. Although sevoflurane anesthesia may have a neuroprotective effect, few studies have shown that sevoflurane is beneficial for neuronal inflammation.

In the current study, we investigated the possible neuroprotective effects of clinical concentrations of sevoflurane on brain neuronal inflammation. We attempted to conduct the experiments in a more clinical manner, so we opted for intraperitoneal LPS injection rather than intracranial LPS injection. We hypothesized that sevoflurane would be beneficial for reducing the incidence of delirium and POCD because it has protective effects in neuronal inflammation. In this study, we investigated whether sevoflurane protects against LPS-induced cognitive dysfunction and investigated the mechanism of the protective effects of sevoflurane on LPS-induced cognitive dysfunction.

Materials and Methods {#s2}
=====================

Ethics approval
---------------

The Animal Care and Use Committee of Tokyo Medical and Dental University approved the study protocol (0160393A and 0170003A).

Experimental mice
-----------------

Six-month-old male C57BL/6NCr strain mice (26--33 g) were used in this study (SLC Japan, Shizuoka, Japan). The mice were housed under a 12-h light--dark cycle (lights on from 08:00 to 20:00), and room temperature was maintained at 21 ± 1°C. The study used 80 mice. The animals were randomly divided into four groups: (1) 60% oxygen for 1 h + saline (Saline group, control mice), (2) 2% sevoflurane (carrier gas: 60% oxygen) preconditioning for 1 h + saline (SEVO group), (3) 60% oxygen for 1 h + LPS injection (LPS group), and (4) 2% sevoflurane (carrier gas: 60% oxygen) preconditioning for 1 h + LPS injection (SEVO + LPS group). Sevoflurane preconditioning was performed 30 min before intraperitoneal LPS injection ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Timeline of the experimental procedure. FC, fear conditioning. Mice were administered 2% sevoflurane or carrier gas only for 1 h before receiving a 5 mg/kg lipopolysaccharide (LPS) or saline intraperitoneal injection. Twenty-four h after LPS injection, brain samples were taken for Western blotting. A fear conditioning test was performed on days 2, 3, and 4.). All mice had *ad libitum* access to water and food. This study employed only male mice to avoid potential variability caused by the estrous cycle \[[@r27]\].

Experimental protocol
---------------------

LPS (Lipopolysaccharides from *Escherichia coli* O55:B5, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in saline at a concentration of 5 mg/kg. Control animals were injected with the same volume of saline (0.1 ml, vehicle). All mice inhaled 2% sevoflurane (in 60% oxygen) for 1 h in a humidified chamber (180 × 180 × 200 mm) at 39 ± 1°C with a total gas flow of 2 l/min.

Fear conditioning test
----------------------

Behavioral studies were performed as described previously \[[@r32], [@r34]\]. Briefly, a conditioning (acquisition) trial was performed 24 h after 5 mg/kg LPS injection. The test comprised three conditioned--unconditioned stimulus pairings separated by 1-min intervals. Each pairing was as follows: unconditioned stimulus, 0.5 mA foot shock for 1 s; conditioned stimulus, 60 dB white noise for 20 s. The unconditioned stimulus was delivered during the last seconds of the conditioned stimulus. A contextual test was performed 24 h after conditioning. The contextual test was performed in the conditioning chamber for 5 min in the absence of white noise. A cued test was performed by presenting a cue (60 dB white noise, 3-min duration) in an alternate context with distinct visual and tactile cues 48 h after conditioning. The freezing response rate was recorded automatically and used to measure fear memory. The freezing percentage during each test was compared between groups.

Western blot analysis
---------------------

We used intraperitoneal injection of 5 mg/kg LPS for the biochemical experiments. At 24 h after the LPS injection, the hippocampus was isolated and quickly frozen at −80°C. Western blot analysis was performed, as described previously \[[@r34]\]. The frozen hippocampus was homogenized in 150 *µ*l homogenization buffer containing 20 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM Na~4~P~2~O~7~, and a protease inhibitor cocktail. The lysate was centrifuged at 14,000 rpm for 15 min at 4°C. The supernatant was removed and stored at −80°C until use. The amount of protein in each sample was measured using a protein assay kit (Pierce BCA Protein Assay Kit, BCA; Pierce, Rockford, IL, USA). Proteins were separated by SDS-PAGE and transferred to PVDF membranes (Trans-Blot^®^ Turbo^TM^ Mini PVDF Transfer Packs, Bio-Rad, Hercules, CA, USA). The primary antibodies included anti-IL-6 (ab6672, rabbit polyclonal, Abcam, Cambridge, MA, USA), anti-IL-1β (ab9722, rabbit polyclonal, Abcam), anti-β-site amyloid precursor protein-cleaving enzyme (BACE) 1 (ab2077, rabbit polyclonal, Abcam), anti-Iba-1 (for Western blotting, rabbit polyclonal, Wako Pure Chemical Industries), and anti-β-actin (AC-15, mouse monoclonal, Sigma-Aldrich, St. Louis, MO, USA). Secondary antibodies included HRP-linked anti-rabbit IgG (ab98493, donkey polyclonal, Abcam) and HRP-linked anti-mouse IgG (NA9310, sheep, GE Healthcare, Little Chalfont, England). β-Actin antibody was used as the loading control. The protein bands were visualized using a chemiluminescence detection system (SuperSignal West Pico, Pierce).

Histopathological evaluation
----------------------------

We injected (intraperitoneal) 5 mg/kg LPS for the immunohistochemistry study to support the Western blot analyses. Immunohistochemical staining was performed as described previously \[[@r34]\]. Briefly, the mice were perfused under intraperitoneal pentobarbital anesthesia 24 h after the 5 mg/kg LPS injection. For immunohistochemistry, 50-*µ*m-thick floating coronal vibratome sections (bregma −2.06 mm) were obtained. Ionized calcium-binding adapter molecule 1 (Iba-1) staining was performed to observe the microglial response. An anti-Iba-1 antibody was used (for immunocytochemistry; rabbit polyclonal, Wako Pure Chemical Industries, Osaka, Japan). The sections were then incubated with horseradish peroxidase (HRP)-linked anti-rabbit IgG (ab98493, donkey polyclonal, Abcam). The Iba-1 signal was visualized using a DAB-nickel substrate (0.05% DAB, 0.05% NiSO~4~, 0.015% H~2~O~2~, 0.05% 1 M Tris-HCl; pH 6.7). Then, the sections were mounted on slides using brushes and dried overnight. Finally, the slides were covered with cover glasses.

Statistical analysis
--------------------

Statistical analysis was performed IBM SPSS Statistics Ver. 24.0 (IBM, Armonk, NY, USA). The data were expressed as the means ± SEM. The levels of protein expression detected by western blot analysis were expressed as a percentage of the control (saline group) value. Data were analyzed using analysis of variance (two-way factorial ANOVA) with a Bonferroni post hoc test. Differences were considered to be statistically significant when *P*\<0.05.

Sample size estimation
----------------------

A sample size of six in each group for the Western blot analysis and 10 in each group for behavior was sufficient to detect a difference in the treatment effect using analysis of variance (ANOVA) with 80% power and a 0.05 significance level (PASS 11.0, NCSS, Kaysville, UT, USA).

Results {#s3}
=======

Evaluation of long-term memory
------------------------------

The 5 mg/kg LPS injection significantly reduced the freezing response in both the contextual ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Long-term memory evaluation using fear conditioning tests in mice with or without 5 mg/kg lipopolysaccharide (LPS) systemic injection. (A) The freezing response in the contextual test (\*\*\**P*\<0.001 for saline vs. LPS; \**P*\<0.05 for LPS vs. sevoflurane \[SEVO\] + LPS; n=10 mice each). (B) The freezing response in the cued test (\*\*\**P*\<0.001 for saline vs. LPS; \*\**P*\<0.01 for LPS vs. SEVO + LPS; n=10 mice each).) and cued ([Fig. 2B](#fig_002){ref-type="fig"}) fear conditioning tests. Sevoflurane preconditioning abrogated this decline in long-term memory function ([Figs. 2](#fig_002){ref-type="fig"}A and B). These results indicated that sevoflurane preconditioning suppresses the impairment of long-term memory caused by intraperitoneal LPS injection.

Evaluation of microglial activation
-----------------------------------

Intraperitoneal injection of 5 mg/kg LPS injection increased microglial activation in the hippocampus, as shown by Iba-1 staining. Sevoflurane preconditioning abolished this effect of LPS injection ([Figs. 3A--D](#fig_003){ref-type="fig"}Fig. 3.Microglial activation in the hippocampus indicated by ionized calcium-binding adapter molecule 1 (Iba-1) staining (scale bar=100 *µ*m). Black dots indicate Iba-1-positive cells in the (A) saline, (B) sevoflurane (SEVO), (C) lipopolysaccharide (LPS), and (D) SEVO + LPS groups (n=4 mice each). (E) Cumulative data showing the Iba-1 levels in the hippocampus in the 24-h period after 5 mg/kg LPS injection in mice (\*\**P*\<0.01 for Saline vs. LPS; \**P*\<0.05 for LPS vs. SEVO + LPS; n=6 mice each).). The hippocampal levels of the microglial activation marker Iba-1 were also elevated after LPS injection, and sevoflurane also inhibited this increase ([Figs. 3E and F](#fig_003){ref-type="fig"}).

Brain inflammation
------------------

The 5 mg/kg LPS injection increased the levels of IL-6 and IL-1β in the hippocampus, and sevoflurane preconditioning suppressed this increase ([Figs. 4A and B](#fig_004){ref-type="fig"}Fig. 4.Expression of inflammation markers in the hippocampus. (A) IL-1β levels 24 h after 5 mg/kg lipopolysaccharide (LPS) injection (\*\**P*\<0.01 for saline vs. LPS; \**P*\<0.05 for LPS vs. sevoflurane \[SEVO\] + LPS; n=6 mice each). (B) IL-6 levels 24 h after 5 mg/kg LPS injection (\*\*\**P*\<0.001 for Saline vs. LPS; \*\**P*\<0.01 for LPS vs. SEVO + LPS; n=6 mice each).).

Aβ accumulation
---------------

Injection of 5 mg/kg LPS increased the levels of β-site amyloid precursor protein-cleaving enzyme (BACE) 1, which resulted in Aβ accumulation, and sevoflurane preconditioning suppressed this increase ([Fig. 5](#fig_005){ref-type="fig"}Fig. 5.The β-site amyloid precursor protein-cleaving enzyme (BACE) 1 levels in the hippocampus 24 h after 5 mg/kg lipopolysaccharide (LPS) injection (\*\*\**P*\<0.001 for saline vs. LPS and for LPS vs. sevoflurane \[SEVO\] + LPS; n=6 mice each).).

Discussion {#s4}
==========

Consistent with previous studies \[[@r3], [@r7], [@r8], [@r23]\], intraperitoneal injection of 5 mg/kg LPS produced an approximately 40% reduction in the freezing response in the contextual and cued fear conditioning tests, indicating that LPS impaired both hippocampus-dependent and hippocampus-independent memory \[[@r32], [@r34]\]. In this study, intraperitoneal injection of 5 mg/kg LPS increased inflammation and Aβ accumulation along with microglial activation in the brain. Importantly, sevoflurane preconditioning prevented intracerebral inflammation, excessive microglial activation, and Aβ accumulation and further prevented the reduction in long-term memory function induced by intraperitoneal LPS injection. These results suggest that sevoflurane preconditioning protected against the long-term memory impairment induced by systematic LPS injection in an animal model of systemic inflammation by alleviating neuronal inflammation.

Accumulated evidence has demonstrated that exacerbated neuronal inflammation is the central step in the development of long-term cognitive impairment \[[@r7], [@r35]\]. Systemic LPS administration increased the levels of IL-6 and IL-1β, two major proinflammatory mediators released by activated microglia and astrocytes. Due to the suppression of proinflammatory mediators, coadministration of minocycline improved the LPS-induced cognitive impairment \[[@r11]\]. This study demonstrated that sevoflurane preconditioning significantly suppressed the LPS-induced IL-6 and IL-1β production, as well as microglial activation in the mouse hippocampus.

Sevoflurane suppressed excessive microglial activation in this study, which means that it inhibited proinflammatory mediators released by activated microglia and astrocytes. Microglial over-activation is the crucial factor involved in brain inflammation \[[@r11], [@r25]\], so we showed that sevoflurane improved long-term memory impairment by suppressing brain inflammation induced by intraperitoneal injection of 5 mg/kg LPS.

BACE1 levels are reported to correlate with the degree of cognitive impairment \[[@r3], [@r7], [@r37]\]. The BACE1 level is used in research on Alzheimer's disease \[[@r2], [@r33]\]. Choi *et al*. \[[@r3]\] reported that obovatol suppressed the LPS-induced BACE1 elevation and improved cognitive impairment. Our results indicated that sevoflurane prevented the learning disability induced by LPS injection by suppressing BACE1.

Anesthesia contributes to the development of postoperative infections and the spread of malignant disease due to the patient's poor health status \[[@r31]\]. Deep anesthesia is independently associated with postoperative mortality \[[@r17]\]. In contrast, Hermann *et al*. \[[@r9]\] reported that administration of the volatile anesthetic sevoflurane significantly improved mortality in a cecal ligation and puncture model. They concluded that volatile anesthetics have beneficial immunomodulatory effects on complex inflammation-mediated conditions in both nonhuman animals \[[@r4], [@r10], [@r20],[@r21],[@r22], [@r29]\] and humans \[[@r1], [@r15], [@r16]\]. The results of this study were consistent with those findings.

We administered 2% sevoflurane for 1 h before the LPS injection based on Li's protocol \[[@r24]\]. In adult mice, the minimum alveolar concentration was found to be 2.5--3.2% \[[@r13], [@r28]\]. The results of the present study showed that in healthy adult mice, 2% sevoflurane did not cause respiratory or circulatory depression. Sevoflurane preconditioning was performed 30 min before intraperitoneal LPS injection as previously described \[[@r24]\]. A 30-min interval is sufficient for full recovery from sevoflurane anesthesia. In addition, the SEVO groups exhibited no hemodynamic changes compared with the control groups.

In the intensive care unit, sevoflurane is better than propofol \[[@r14]\] and midazolam \[[@r6]\] for sedation in acute respiratory distress syndrome in terms of the inflammatory response and oxygenation. Suppression of the excessive immune response to which sevoflurane contributes might be beneficial for patients with both systemic and neuronal inflammatory. The suppression of neuronal inflammation might be beneficial for postoperative delirium and POCD.

Our study clearly shows significant beneficial effects of sevoflurane preconditioning via the inhibition of microglial activation. However, this requires validation in other animal models. Different anesthesia protocols may give different outcomes. For example, there are reports that exposure to sevoflurane causes an inflammatory reaction and long-term memory impairment in aged and neonatal rodents \[[@r26], [@r32], [@r34]\].

We did not measure peripheral cytokine levels in this experiment. It would have been better to measure both intracranial cytokine levels and peripheral cytokine levels at the same time.

Conclusions
-----------

We demonstrated that sevoflurane preconditioning prevented long-term memory impairment in mice following systemic LPS administration by decreasing excessive microglial activation, inflammation, and Aβ accumulation. This study supports the hypothesis that sevoflurane preconditioning might be beneficial for neuronal inflammatory patients. Sevoflurane might also be beneficial for reducing delirium and POCD.
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